WO2014192974A1 - Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer - Google Patents

Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer Download PDF

Info

Publication number
WO2014192974A1
WO2014192974A1 PCT/JP2014/064902 JP2014064902W WO2014192974A1 WO 2014192974 A1 WO2014192974 A1 WO 2014192974A1 JP 2014064902 W JP2014064902 W JP 2014064902W WO 2014192974 A1 WO2014192974 A1 WO 2014192974A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
lgr6
antibody
seq
amino acid
Prior art date
Application number
PCT/JP2014/064902
Other languages
English (en)
Japanese (ja)
Inventor
博幸 里深
康文 村上
Original Assignee
株式会社オーダーメードメディカルリサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社オーダーメードメディカルリサーチ filed Critical 株式会社オーダーメードメディカルリサーチ
Priority to EP14804893.7A priority Critical patent/EP3006942A4/fr
Priority to US14/894,254 priority patent/US20160116478A1/en
Priority to CA2913924A priority patent/CA2913924A1/fr
Priority to JP2015519989A priority patent/JPWO2014192974A1/ja
Publication of WO2014192974A1 publication Critical patent/WO2014192974A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Abstract

L'invention concerne un réactif pour la détection et le diagnostic du cancer, ledit réactif contenant des anticorps monoclonaux ou des fragments de ceux-ci contre LGR6 pour la détection et le diagnostic du cancer.
PCT/JP2014/064902 2013-05-30 2014-05-29 Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer WO2014192974A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP14804893.7A EP3006942A4 (fr) 2013-05-30 2014-05-29 Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer
US14/894,254 US20160116478A1 (en) 2013-05-30 2014-05-29 Reagent including anti-lgr6 antibodies for detection and diagnosis of cancer
CA2913924A CA2913924A1 (fr) 2013-05-30 2014-05-29 Reactif contenant des anticorps anti-lgr6 pour la detection et le diagnostic du cancer
JP2015519989A JPWO2014192974A1 (ja) 2013-05-30 2014-05-29 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013114150 2013-05-30
JP2013-114150 2013-05-30

Publications (1)

Publication Number Publication Date
WO2014192974A1 true WO2014192974A1 (fr) 2014-12-04

Family

ID=51988985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/064902 WO2014192974A1 (fr) 2013-05-30 2014-05-29 Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer

Country Status (5)

Country Link
US (1) US20160116478A1 (fr)
EP (1) EP3006942A4 (fr)
JP (1) JPWO2014192974A1 (fr)
CA (1) CA2913924A1 (fr)
WO (1) WO2014192974A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207414A1 (fr) * 2015-06-25 2016-12-29 Universitaet Des Saarlandes Procédé de diagnostic amélioré pour un cancer induit par hpv et criblage et diagnostic de lésion précancéreuse
US9598497B2 (en) 2012-07-13 2017-03-21 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
US9610348B2 (en) 2007-07-02 2017-04-04 Oncomed Pharmaceuticals, Inc Compositions and methods for treating and diagnosing cancer
US9644034B2 (en) 2011-07-15 2017-05-09 Oncomed Pharmaceuticals, Inc. Anti-RSPO2 antibodies and uses thereof
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005046065A (ja) 2003-07-29 2005-02-24 Hitachi Ltd 細胞回収方法及び細胞回収装置
JP2006519376A (ja) 2003-02-27 2006-08-24 ダコサイトメーション・デンマーク・アクティーゼルスカブ 免疫組織化学、免疫細胞化学および分子細胞遺伝学のための標準
WO2010016766A2 (fr) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène
JP2010532169A (ja) 2007-07-02 2010-10-07 オンコメッド ファーマシューティカルズ インコーポレイテッド がんを処置および診断するための組成物および方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519376A (ja) 2003-02-27 2006-08-24 ダコサイトメーション・デンマーク・アクティーゼルスカブ 免疫組織化学、免疫細胞化学および分子細胞遺伝学のための標準
JP2005046065A (ja) 2003-07-29 2005-02-24 Hitachi Ltd 細胞回収方法及び細胞回収装置
JP2010532169A (ja) 2007-07-02 2010-10-07 オンコメッド ファーマシューティカルズ インコーポレイテッド がんを処置および診断するための組成物および方法
WO2010016766A2 (fr) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Annals of Internal Medicine", vol. 137, 2002, pages: 305 - 312
"Molecular Cloning, A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
CARMEN, S. ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203
ENDOCR RELAT CANCER, vol. 9, 2002, pages 75 - 85
J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
JAMA, vol. 269, 1993, pages 1262 - 1267
KUROIWA, Y. ET AL., NUC. ACIDS RES., vol. 26, 1998, pages 3447 - 3448
MODERN MEDIA, vol. 55, no. 7, 2009
MOLECULAR CANCER, vol. 9, 2010, pages 166
NATURE, vol. 321, 1986, pages 522 - 525
PLOS ONE, vol. 7, 2012, pages E37137
PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851 - 6855
QUEEN C ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
SAMBROOK J. ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SCIENCE, vol. 337, 2012, pages 730 - 735
See also references of EP3006942A4
SIRIWARDENA, D. ET AL., OPTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431
STEFFEN JS ET AL.: "LGR4 and LGR6 are differentially expressed and of putative tumor biological significance in gastric carcinoma", VIRCHOWS ARCH, vol. 461, no. 4, 2 August 2012 (2012-08-02), pages 355 - 365, XP035118936 *
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1977, pages 133 - 143
TOMIZUKA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727
VIRCHOWS ARCH., vol. 461, 2012, pages 355 - 365
WORMSTONE, I. M. ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE., vol. 43, no. 7, 2002, pages 2301 - 2308
YOSHIDA, H. ET AL.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9610348B2 (en) 2007-07-02 2017-04-04 Oncomed Pharmaceuticals, Inc Compositions and methods for treating and diagnosing cancer
US9717794B2 (en) 2007-07-02 2017-08-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US9644034B2 (en) 2011-07-15 2017-05-09 Oncomed Pharmaceuticals, Inc. Anti-RSPO2 antibodies and uses thereof
US9598497B2 (en) 2012-07-13 2017-03-21 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
WO2016207414A1 (fr) * 2015-06-25 2016-12-29 Universitaet Des Saarlandes Procédé de diagnostic amélioré pour un cancer induit par hpv et criblage et diagnostic de lésion précancéreuse

Also Published As

Publication number Publication date
US20160116478A1 (en) 2016-04-28
JPWO2014192974A1 (ja) 2017-02-23
CA2913924A1 (fr) 2014-12-04
EP3006942A4 (fr) 2016-11-30
EP3006942A1 (fr) 2016-04-13

Similar Documents

Publication Publication Date Title
JP7344797B2 (ja) 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
WO2014192974A1 (fr) Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer
KR20160065876A (ko) 췌장 종양의 검출 방법, 항체 및 췌장 종양 검출용 키트
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
JP2012021943A (ja) 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
JP5686361B2 (ja) 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
AU2011298090B2 (en) Antibody against colorectal cancer marker
WO2011090166A1 (fr) Marqueur de cancer de l'œsophage
CN103429617B (zh) 包含抗-ck8/18复合物自身抗体的标记物及其诊断癌症的用途
WO2016052756A1 (fr) Réactif permettant de détecter ou de diagnostiquer des cellules cancéreuses à capacité invasive élevée
EP2738250B1 (fr) Anticorps anti-beta1,6-N-acetylglucosaminyltransferase 5B pour la détection du cancer épithélial de l'ovaire et méthode pour le diagnostic du cancer épithélial de l'ovaire
US20120122126A1 (en) Anti-psk antibody
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
JP5229866B2 (ja) 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
TW201840588A (zh) 抗ｇｐｒ２０抗體
EP2738252B1 (fr) Anticorps pour la détection d'un marqueur du cancer épithélial de l'ovaire et méthode pour le diagnostic du cancer épithélial de l'ovaire
JP7023942B2 (ja) 卵巣癌バイオマーカーおよびその使用
JP5429723B2 (ja) 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
KR100996486B1 (ko) 인체 무등(ｍｕｄｅｎｇ) 단백질에 대한 단일클론 항체
JP2017133884A (ja) タンパク質−微粒子複合体、及びそれを用いた標的生体物質の検出方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14804893

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015519989

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14894254

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2913924

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014804893

Country of ref document: EP